Metformin Generics Are "Approvable"; Barr Says Delay Helps Other Generics
Executive Summary
The delay in FDA approval of generic versions of Bristol-Myers Squibb's Glucophage (metformin) will reduce Barr's profitability from the product by giving other generic companies time to increase their manufacturing capacity, Barr said.
You may also be interested in...
Glucophage Generics Enter Market: Bristol Says It Will Not Sue Agency
Generic versions of metformin will carry labeling that refers prescribers to Bristol-Myers Squibb's Glucophage label for information on pediatric patients
Glucophage Generics Enter Market: Bristol Says It Will Not Sue Agency
Generic versions of metformin will carry labeling that refers prescribers to Bristol-Myers Squibb's Glucophage label for information on pediatric patients
Bristol Metformin/Glyburide Patent Could Extend Glucophage Exclusivity
Bristol has a patent application pending that covers low-dose combinations of metformin (Glucophage) and glyburide